
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management.
Speaking at a Bank of America fireside chat, President and CEO Michael Carrel and CFO Angela Wirick discussed the company’s growth targets, profitability trajectory, competitive positioning and clinical trial pipeline. AtriCure delivered 15% revenue growth in 2025 and is guiding for 12% to 14% growth in 2026.